It was not "great" to come off it. It was necessary because shills like you (sorry icon I like your posts but this guy is 99% negative and full of it so we agree to disagre) have been trying to stop imetelstat since Dec. 2013. He suffered as a result. So those who get on it and get a CR will have to stay on it forever without interruption if they can afford it and don't have to fly 2000 miles every 3 weeks to get - as I have posted. So you well know this is more FUD and if anyone trusts you it is their misjudgement. You sound just like jacosa, beaver, snd black wrapped in one. I will never respond to you again - just leave us out of your efforts to devalue
Geron. Interesting how you usually show up only when stock is hit hard.
ligas - I identified you as Incy shill long ago. Cabe man's rational, fact-based counter to your contrived nonsense is exactly correct. I can only offer 4 additional facts: 1) John was put on low dose when he returned to imetelstat treatment 2nd time. He was on low dose (7.5) as maintenance when he voluntarily left the trial. His blood counts normalized much more slowly the 2nd time on imetelstat because of the lower dose start and not the high (riskier) 1st start dose (9.5) that got his initial rapid fire response. And, unlike the new trial patients, he has the unique added advantage of prior imetelstst in his system and has never pre-poisened his system with useless jakafi. 2) Four doses is 12 weeks of treatment. I doubt any dying patient with only palliative options will give up imetelstat in 12 weeks especially with relatively minimal side effects. Many MF patients responded after 12 weeks (review published response data before posting blather). 3) Cancer patient caregivers know EXACTLY the medication protocol of their loved one. Their lives depend on it. On that aspect alone, you repost an obviously questionable post. 4) Facebook is a wholly unreliable source with no vetting or verification just like this board. See how easy it was for you to pose as phony patient and get access to the site as a "patient"? Easy enough to set up a mpn/incy propaganda 'front' page with untrue "patient" postings by the anti-imetelstat faction to try to stall incy complete, immediate collapse completely because jakafi does not work and imetelstat does (and FDA is bought and sold, too). Nonetheless, you bet on the wrong drug so - in the words of another poster - go away with your pseudo concern for patients that only thinly disguises your 'ruin imetelstat by rumor' campaign. The campaign that you, and your ilk, launched the day Mayo announced the 1st imetelstat CR. How much incy blood money have you made since (while shorting geron for good measure)? Keeping trying to delay delay imetelstat approval - you have kept it from dying patients for 3 years since the 1st CR. However, sooner or later you will go down - and I will be dancing on your grave.
For those interested, it seems 1951 patients can't go to Imbark or Imerge study centers - only Mayo. Other centers managing new patients and trials. Can't overwhelm them with the original MF patients still alive and taking up valuable infusion room time! Once approved our insurances will pay. That we have established. So - for the record - "free" is little incentive for the way patients often become big pharm pawns in clinical trials. That is why such a small % of cancer patients enroll at all. Of course, imet (and Tefferi) is different and especially now that patients know side effects and risks comparatively minimal and it works at multiple levels for durable time. As for paperwork, part say helping drug get approved. I guess gamers just need INCY investors have plenty of time to divest slowly IMO.
John infused today and same good news to report so there is much reason to celebrate regardless. And, I think you cannot time this - one day the old good news and the new good news will explodin a grand collision of great news that takes wing.
cw - I ask myself this everyday with same frustration. John (and not only him) will have first infused imetelstat 3 years ago in April! It is safe. He has remission for 2nd time after stopping and starting again. Why does he have to keep flying to cold Rochester - a 3 day journey to the endless trial. I think because investors in competing companies need time to unravel and reravel hedge investments. But I know nothing about investing - I specialize in children whose future worries me based on little I now know about the lack of fair play in the financial sector.
yes mangy - i like to call imetelstat a chemical stem cell transplant without horrendous side effects and risk of death.
Dear Boxer, I only have some very general 2nd hand information but all is good. And, I also have no reason to believe otherwise.
With regard to John's original trial that openned to new enrollment, and with some original MF patients starting 3 (or almost 3 years ago), the survival speaks for itself. As for the newer ImBark trial, it continues to expand, after 12+ week preliminary data is available to JJ/Geron so what might you conclude?
My speculation on the MDS trial IMerge is that given the mutational profiles of MDS, and the anemia associated, results should follow MF results.
I have no explanation for the stock price other than bad market and JJ/Geron/Mayo have a plan for strategic news release so lack of news - however this is my speculation.
Lastly, John heading to Mayo again Sunday for 3 week infusion. He is great. I honestly don't think the trials would be on-going if he is the only one showing benefit.
Also - think about the song choices at last presentation and the definitions of " imbark" and "Imerge".
Also - don't forget there was a public announcement at time of JJ partnership about a working group involving JJ/Geron/Mayo so you can probably safely assume all hands on deck.
Lastly, Dr. Tefferi published a new article on dearth of treatment options for MDS and need for new drug. Those "we have no or inadequate treatment" publications would seem to go a long way with FDA if/when attached to various applications.
This is my impression. Do your own due diligence. Happy Day! PS How can I ignore a boxe and pug dog lover?
hello friends - a quick response to the trolls, players, and FUD on this thread. I rarely respond to the BS on the board, however, when Geron is unfairly pounded like during the infamous "hold", I sometimes must clarify. 1) "water cooler" was metaphor for occassionally patients, doctors, nurses, staff informally and generally discussing diseases, test results, medications, trials, and more. 2) sometimes doctors very generally let patients know how others are doing and patients do know other patients and do talk among themselves, 3) "good spirits" are often found in cancer centers especially when your drug is working or you are feeling a little better, 4) you are correct that one person is not proof of anything however smart people know it is more than one person and that is publically known, 5) yes since Dr. Tefferi is John's hemotology oncologist we know when he is traveling as John is seen by another staff member on those visits, 6) since John has been in the trial since the first cohort we do know more or less what is "going on" with imet, 7) patients in experimental trials do care about the company - if the company goes down then the drug goes down and it is never available close to home as standard of carea and John dies, and 8) I dont' travel with John as he is healthy enougth (and the treatment is now routine enough) to make the long, cold trip to Mayo alone so I am usually not with him at Mayo. My reports are 2nd hand (although sometimes I talk to his doctors at Mayo if the situaion warrants) so.due your own due diligence. I do not rely on what you tell me and you should not rely on what I tell you. However, civil discourse is a mark of cogntive and emotional intelligence. Some posters on this thread (and all over this board) seem to have joined the angry beaver club.
PS - I would focus on MDS and other myeloid cancers and pre-cancers as opportunities for eventual market expansion and MF as the most likely path to eventual approval and distribution.
big - you are all forgetting that MF studies are driving the approval train. MDS just market expansion studies. The MF data in 2 studies alone could prompt continuation agreement. It was and always will be 1951 and it's post jak counter study with preliminary data pending anytime.
Interesting Tefferi new article below. A few other interesting articles from him and colleagues, too. However, I think this one could suggest attempt to morphologically distinguish between ET and Pre-MF (and morphological variants of PV) to better identify (and officially reclassify) some ET as Pre-MF under WHO criteria so can open door to treat subset of ET (and maybe PV) - as well as MF and MDS - with imet. Just my impression.
Barbui T, et al. Am Am J Hematol. Myeloproliferative neoplasms: Morphology and clinical practice. 2015 Dec 30. doi: 10.1002/ajh.24288. [Epub ahead of print]l .
John at Mayo last week. General "talk" at water cooler good. John health and blood counts very, very good. Same old great news on that account. Did not see Dr. Tefferi or Dr. Gagnat this time. Both very busy and Dr. T. traveling. We expect a very happy new year. Patients are patient - you should be, too, although it is very hard and frustrating. You are as close to the raw emotion of participating in an experimental trial as you can get without infusing. What I have learned: cancer cures - or as close to it as possible - don't come easy when there are powerful competing interests. But to the science the victory. And, I still think registry studies are in our near future under ODD designations. PS Sorry for not posting more but you should know the story by now and can likely guess the ending and we are busy living a happy life thanks to imet and all it's inventors, advocates, and supporters. Thank you again for not selling. Cancer curing drugs in development need believers not players.
There is no reason not to believe this good result as it would be statistically be probable extrapolating from known trial results. This claim is also similar to John's response - and other prior very durable responses. Given short time imet action, one could reasonably expect data update (positive imo) in near term. Yes Santa was flying under the radar this year and now on to a happy 2016 for patients and investors. By the way, Dr. Gangat is one of Dr.Tefferi's Mayo proteges. John often sees her when Dr. Tefferi is out of the clinic as he is very busy these days (see prior cabe post). She is a natural choice to direct the 1951 continuing study while Dr. Tefferi works with JJ (and Geron) on all things imet.
Iwas - yes exactly. This seems to only increase platelets. Only one issue. Imetelstat clears marrow so all blood - white red platelets - normalize.
ped - I continue to believe they keep emphasizing Imetelstat is best available therapy because that is the FDA key that unlocks the ODD door. There is a provision for FDA pre-approval distribution in terminal cancers if drug meets 3 criteria - that is one of them.
And AML and others. Note: I think ET can go forward in Europe. I think may know which ET likely to transform to MF so can identify who needs it early.
yes - and same pisitive effect across the platform of genetically similar myeloid blood cancers ET MF MDS.
Based on my limited knowledge, age not differentiating variable. Both younger and older responded. All in Mayo IST very sick with advanced disease progression (intermediate and high risk) so one can assume not new diagnosis. And long enough to become resistant to other drugs (hydroxurea and jakafi).
In light of such aggregated enthusiastically shared medically validated great news, the basher has gone soft now hoping to salvage a shred on influence with the naive. Beware.
Soft basher: Yes good, but we will just have to wait and see next year. Wait for some trial data.
Right...like we don't have enough actionable data with more right around the corner. Johnson and Johnson not waiting. Patients need it and want it now. We should be on the 1st train leaving the station.
1. A now publically acknowledged platform drug for ET and the myeloid cancers that are all genetic siblings or cousins. ET and myeloid blood disorders likely only the first plank in the platform.
2. Worldwide trials (read distribution centers) operational in record-time.
3. No safety issues and minimal side effects. (This hammer finally taken out of basher hands once and for all - you know the bashers with the competing interests).
4. Efficacy that meets - and then /remarkably exceeds - standard of care across the platform.
5. Efficacy that comes in at lightening speed.
6. ODD for MF in US and Europe that is de facto fast track.
7. A bounty of remarkable phase 1 and 2 data with more preliminary data to confirm existing data pending any day now
8. Phase 3 MDS ready to roll if not already rolling. Unheard of in 10 years.
9. Patents, cash, tax credits, and JJ acting as Geron's body guard.
10. Milestone payment looming and opt in or buy out decision sooner not later.
As cabeman pointed out, Dr. T. initially thought (and so did first patients) that the trial could be risky expecting cytopenias because imetelstat worked so well so fast in ET. However, myelosuppression was not commesureate with effect. John neutrophils hit .8 and .9. He would keep taking blood tests until he got the minimum 1 and then kept infusing with dosage adjustment without interruption as cytopenia dimished. When he restarted again months later, no myelosuporession at all and no resistence/tolerance with same quick response.